Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy

Chinese Medical Journal

Volumn 123, Issue 17, 2010, Pages 2454-2460

  Dong, Fang ^a   Ha, Xiao Qin ^a  

^a LANZHOU GENERAL HOSPITAL   (China)

Author keywords

Endothelial progenitor cells; Pathological neovascularization; Tumor therapy

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; ERYTHROPOIETIN; MATRIX METALLOPROTEINASE; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; DNA MODIFICATION; ENDOTHELIAL PROGENITOR CELL; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PREDICTION; PROGNOSIS; REVIEW; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE THERAPY; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CXCR4; STEM CELLS;

EID: 79851479215     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.17.030     Document Type: Review

References (72)

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
2. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95: 3106-3112.
3. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007; 35: 1109-1118.
4. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003; 101: 168-172.
5. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498-508.
6. Nagano M, Yamashita T, Hamada H, Ohneda K, Kimura K, Nakagawa T, et al. Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. Blood 2007; 110: 151-160.
7. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93: e17-e24.
8. Zhang W, Zhang G, Jin H, Hu R. Characteristics of bone marrow-derived endothelial progenitor cells in aged mice. Biochem Biophys Res Commun 2006; 348: 1018-1023.
9. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
10. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999; 18: 3964-3972.
11. Ishizawa K, Kubo H, Yamada M, Kobayashi S, Numasaki M, Ueda S, et al. Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett 2004; 556: 249-252.
12. Bruno S, Bussolati B, Scacciatella P, Marra S, Sanavio F, Tarella C, et al. Combined administration of G-CSF and GM-CSF stimulates monocyte-derived pro-angiogenic cells in patients with acute myocardial infarction. Cytokine 2006; 34: 56-65.
13. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med 2005; 56: 79-101.
14. Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, Assmus B, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 2003; 107: 2134-2139.
15. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001; 938: 36-45; discussion 45-37.
16. + stem cells from bone-marrow microenvironment. Nat Med 2002; 8: 841-849.
17. Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003; 107: 3059-3065.
18. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-1346.
19. Packard JC. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
20. Wang CH, Verma S, Hsieh IC, Chen YJ, Kuo LT, Yang NI, et al. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol 2006; 41: 34-43.
21. Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 2005; 183: 163-167.
22. Sandri M, Adams V, Gielen S, Linke A, Lenk K, Krankel N, et al. Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation 2005; 111: 3391-3399.
23. Steiner S, Niessner A, Ziegler S, Richter B, Seidinger D, Pleiner J, et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 2005; 181: 305-310.
24. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114: 623-633.
25. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-1376.
26. Santhanam AV, d'Uscio LV, Peterson TE, Katusic ZS. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 2008; 29: 1451-1455.
27. Zheng H, Fu G, Dai T, Huang H. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 2007; 50: 274-280.
28. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009; 19: 329-337.
29. Stoll BR, Migliorini C, Kadambi A, Munn LL, Jain RK. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003; 102: 2555-2561.
30. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A 2005; 102: 18111-18116.
31. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
32. Krenning G, van Luyn MJ, Harmsen MC. Endothelial progenitor cell-based neovascularization: implications for therapy. Trends Mol Med 2009; 15: 180-189.
33. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009; 19: 329-337.
34. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124: 175-189.
35. Morimoto H, Takahashi M, Shiba Y, Izawa A, Ise H, Hongo M, et al. Bone marrow-derived CXCR4+ cells mobilized by macrophage colony-stimulating factor participate in the reduction of infarct area and improvement of cardiac remodeling after myocardial infarction in mice. Am J Pathol 2007; 171: 755-766.
36. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003; 107: 1322-1328.
37. Capoccia BJ, Gregory AD, Link DC. Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1- dependent fashion. J Leukoc Biol 2008; 84: 760-768.
38. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha→ hypoxia response element→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000; 60: 6248-6252.
39. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003; 31: 1171-1177.
40. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703.
41. Xu J, Liu X, Jiang Y, Chu L, Hao H, Liua Z, et al. MAPK/ERK signalling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell. J Cell Mol Med 2008; 12: 2395-2406.
42. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8: 1223-1234.
43. Kaminski A, Ma N, Donndorf P, Lindenblatt N, Feldmeier G, Ong LL, et al. Endothelial NOS is required for SDF-1alpha/CXCR4-mediated peripheral endothelial adhesion of c-kit+ bone marrow stem cells. Lab Invest 2008; 88: 58-69.
44. + cells. Stem Cells 2007; 25: 211-219.
45. De Falco E, Porcelli D, Torella AR, Straino S, Iachininoto MG, Orlandi A, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004; 104: 3472-3482.
46. Marzo F, Lavorgna A, Coluzzi G, Santucci E, Tarantino F, Rio T, et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 2008; 26: 183-187.
47. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228: 1-14.
48. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 2007; 117: 1068-1077.
49. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445: 776-780.
50. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 2007; 104: 3219-3224.
51. Wang L, Wang YC, Hu XB, Zhang BF, Dou GR, He F, et al. Notch-RBP-J signaling regulates the mobilization and function of endothelial progenitor cells by dynamic modulation of CXCR4 expression in mice. PLoS One 2009; 4: e7572.
52. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found Symp 2007; 283: 106-120; discussion 121-105, 238-141.
53. Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, et al. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 2009; 15: 4058-4065.
54. Doyle B, Metharom P, Caplice NM. Endothelial progenitor cells. Endothelium 2006; 13: 403-410.
55. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436.
56. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6: 835-845.
57. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106: 3058-3061.
58. Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 2006; 66: 7341-7347.
59. Naik RP, Jin D, Chuang E, Gold EG, Tousimis EA, Moore AL, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 2008; 107: 133-138.
60. Yu D, Sun X, Qiu Y, Zhou J, Wu Y, Zhuang L, et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 2007; 13: 3814-3824.
61. Georgiou HD, Namdarian B, Corcoran NM, Costello AJ, Hovens CM. Circulating endothelial cells as biomarkers of prostate cancer. Nat Clin Pract Urol 2008; 5: 445-454.
62. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-1787.
63. Bolontrade MF, Zhou RR, Kleinerman ES. Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin Cancer Res 2002; 8: 3622-3627.
64. Murakami J, Li TS, Ueda K, Tanaka T, Hamano K. Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy. Int J Cancer 2009; 124: 1685-1692.
65. Palumbo B, Palumbo R, Sinzinger H. Radioidine therapy temporarily increases circulating endothelial cells and decreases endothelial progenitor cells. Nucl Med Rev Cent East Eur 2003; 6: 123-126.
66. Heissig B, Rafii S, Akiyama H, Ohki Y, Sato Y, Rafael T, et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 2005; 202: 739-750.
67. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002; 105: 732-738.
68. Griese DP, Achatz S, Batzlsperger CA, Strauch UG, Grumbeck B, Weil J, et al. Vascular gene delivery of anticoagulants by transplantation of retrovirally-transduced endothelial progenitor cells. Cardiovasc Res 2003; 58: 469-477.
69. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004; 109: 1769-1775.
70. Debatin KM, Wei J, Beltinger C. Endothelial progenitor cells for cancer gene therapy. Gene Ther 2008; 15: 780-786.
71. Kyrtatos PG, Lehtolainen P, Junemann-Ramirez M, Garcia-Prieto A, Price AN, Martin JF, et al. Magnetic tagging increases delivery of circulating progenitors in vascular injury. JACC Cardiovasc Interv 2009; 2: 794-802.
72. Gastens MH, Goltry K, Prohaska W, Tschope D, Stratmann B, Lammers D, et al. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Cell Transplant 2007; 16: 685-696.